title: Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.
abstract: The modulating effect of serotonergic drugs on the striatal dopamine neurotransmission has remained controversial, and there are no published data on serotonin-dopamine interaction obtained from living human brain. Citalopram is a selective serotonin reuptake inhibitor widely used in the treatment of depression (20-40 mg/day). We measured the effects of acute (20 mg, per os) and chronic (20 mg/day for 14 days) doses of citalopram and placebo intake on [11C]-raclopride binding to striatal D2-receptors in eight healthy volunteers by using positron emission tomography. Although the effect magnitude was not large, the results indicate that chronic citalopram intake slightly decreases the raclopride binding which may reflect increased dopamine release in the striatum. In addition, after 14 days there was a high correlation between the citalopam plasma levels and the decrease in the [11C]-raclopride binding in both the caudate and the putamen, although statistically significant effect in the raclopride binding potential was more pronounced in the putamen. This report suggests functional interaction of brain dopaminergic and serotonergic systems in vivo in man.
authors.affiliation: Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Tiihonen
authors.forename: M
authors.initials: M
authors.lastname: Kuoppamäki
authors.forename: K
authors.initials: K
authors.lastname: Någren
authors.forename: J
authors.initials: J
authors.lastname: Bergman
authors.forename: E
authors.initials: E
authors.lastname: Eronen
authors.forename: E
authors.initials: E
authors.lastname: Syvälahti
authors.forename: J
authors.initials: J
authors.lastname: Hietala
mesh_terms: D000328:Adult; D015283:Citalopram / Q000097:blood / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D018492:Dopamine Antagonists / Q000378:metabolism; D006801:Humans; D008297:Male; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism; D012457:Salicylamides / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000494:pharmacology*; D014055:Tomography, Emission-Computed
chemical_list: D015283:Citalopram; D018492:Dopamine Antagonists; D020891:Raclopride; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D017367:Selective Serotonin Reuptake Inhibitors